Pinnacle Associates’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.1M Buy
104,077
+1,280
+1% +$169K 0.14% 146
2026
Q1
$14.3M Buy
102,797
+3,169
+3% +$444K 0.18% 124
2025
Q4
$12.2M Sell
99,628
-3,713
-4% -$451K 0.16% 138
2025
Q3
$11.5M Buy
103,341
+1,525
+1% +$173K 0.15% 148
2025
Q2
$11.3M Buy
101,816
+434
+0.4% +$46.2K 0.16% 141
2025
Q1
$11.4M Sell
101,382
-1,167
-1% -$120K 0.17% 137
2024
Q4
$9.47M Buy
102,549
+42,735
+71% +$3.85M 0.13% 169
2024
Q3
$4.85M Sell
59,814
-39,331
-40% -$3M 0.08% 235
2024
Q2
$6.8M Buy
99,145
+40,122
+68% +$2.68M 0.11% 199
2024
Q1
$4.32M Sell
59,023
-791
-1% -$60.8K 0.07% 260
2023
Q4
$4.85M Buy
59,814
+1,033
+2% +$80.4K 0.08% 238
2023
Q3
$4.41M Sell
58,781
-3,701
-6% -$285K 0.08% 240
2023
Q2
$4.82M Sell
62,482
-2,384
-4% -$190K 0.08% 240
2023
Q1
$5.38M Sell
64,866
-3,274
-5% -$271K 0.11% 195
2022
Q4
$5.85M Sell
68,140
-1,815
-3% -$144K 0.13% 185
2022
Q3
$4.32M Sell
69,955
-6,282
-8% -$396K 0.1% 212
2022
Q2
$4.71M Sell
76,237
-5,470
-7% -$339K 0.1% 208
2022
Q1
$4.86M Sell
81,707
-5,549
-6% -$355K 0.09% 223
2021
Q4
$6.34M Sell
87,256
-14,526
-14% -$1M 0.11% 199
2021
Q3
$7.11M Sell
101,782
-1,433
-1% -$101K 0.13% 179
2021
Q2
$7.11M Sell
103,215
-15,861
-13% -$1.06M 0.13% 172
2021
Q1
$7.7M Sell
119,076
-4,734
-4% -$305K 0.15% 158
2020
Q4
$7.21M Sell
123,810
-58,146
-32% -$3.51M 0.15% 158
2020
Q3
$11.5M Sell
181,956
-8,634
-5% -$599K 0.27% 102
2020
Q2
$14.7M Sell
190,590
-11,582
-6% -$888K 0.36% 77
2020
Q1
$15.1M Buy
202,172
+2,594
+1% +$179K 0.46% 65
2019
Q4
$13M Sell
199,578
-25,780
-11% -$1.68M 0.28% 96
2019
Q3
$14.3M Sell
225,358
-1,881
-0.8% -$123K 0.34% 81
2019
Q2
$15.4M Sell
227,239
-2,771
-1% -$182K 0.36% 76
2019
Q1
$15M Buy
230,010
+4,813
+2% +$320K 0.34% 84
2018
Q4
$14.1M Sell
225,197
-39,549
-15% -$2.76M 0.36% 76
2018
Q3
$20.4M Sell
264,746
-12,674
-5% -$957K 0.42% 65
2018
Q2
$19.7M Sell
277,420
-12,685
-4% -$896K 0.4% 69
2018
Q1
$21.9M Sell
290,105
-1,868
-0.6% -$148K 0.43% 63
2017
Q4
$20.9M Sell
291,973
-8,609
-3% -$654K 0.4% 76
2017
Q3
$24.4M Sell
300,582
-2,067
-0.7% -$158K 0.45% 67
2017
Q2
$21.4M Buy
302,649
+8,926
+3% +$594K 0.41% 70
2017
Q1
$19.9M Sell
293,723
-6,082
-2% -$428K 0.38% 75
2016
Q4
$21.5M Sell
299,805
-16,768
-5% -$1.25M 0.43% 67
2016
Q3
$25M Buy
316,573
+15,137
+5% +$1.23M 0.5% 60
2016
Q2
$25.1M Buy
301,436
+55,899
+23% +$4.96M 0.54% 53
2016
Q1
$22.6M Buy
245,537
+8,989
+4% +$811K 0.48% 58
2015
Q4
$23.9M Buy
236,548
+4,399
+2% +$458K 0.5% 54
2015
Q3
$22.8M Buy
232,149
+21,617
+10% +$2.4M 0.5% 56
2015
Q2
$24.6M Sell
210,532
-17,398
-8% -$1.9M 0.46% 62
2015
Q1
$22.4M Sell
227,930
-17,157
-7% -$1.74M 0.42% 67
2014
Q4
$23.1M Sell
245,087
-9,839
-4% -$1.02M 0.45% 63
2014
Q3
$27.1M Sell
254,926
-11,015
-4% -$1.08M 0.55% 49
2014
Q2
$22M Sell
265,941
-684
-0.3% -$53.2K 0.43% 64
2014
Q1
$18.9M Sell
266,625
-20,564
-7% -$1.61M 0.37% 75
2013
Q4
$21.6M Sell
287,189
-3,718
-1% -$259K 0.42% 67
2013
Q3
$18.3M Buy
290,907
+32,630
+13% +$1.95M 0.38% 73
2013
Q2
$13.2M Buy
+258,277
New +$13.5M 0.3% 94

Other funds holding GILD

Pinnacle Associates's GILD Position: Q2 2026 in Review

Pinnacle Associates increased its Gilead Sciences (GILD) stake by 1.2% in Q2 2026, buying an estimated $169K and bringing the position to 104,077 shares worth $13.1M. The position accounts for 0.14% of the portfolio, ranked #146.

Pinnacle Associates first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $27.1M in Q3 2014. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Pinnacle Associates held 104,077 shares of Gilead Sciences worth $13.1M as of Q2 2026.
  • Pinnacle Associates bought 1,280 Gilead Sciences shares in Q2 2026, an estimated $169K.
  • Gilead Sciences made up 0.14% of Pinnacle Associates's portfolio in Q2 2026, its #146 holding.
  • Pinnacle Associates first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Pinnacle Associates's Gilead Sciences position peaked at $27.1M in Q3 2014.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.